Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Suizenji in Patients With Unresectable Pancreatic Cancer
Sponsor: SONIRE Therapeutics Inc.
Summary
The purpose of this study is to evaluate the safety and efficacy of standard chemotherapy with or without a novel High Intensity Focused Ultrasound system (Code: Suizenji) in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy.
Official title: A Randomized Controlled Study of Suizenji in Patients With Unresectable Pancreatic Cancer
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2023-01-31
Completion Date
2027-05-31
Last Updated
2026-03-16
Healthy Volunteers
No
Conditions
Interventions
Suizenji
HIFU treatment
Nal-IRI/FL
Nanoliposomal irinotecan, Fluorouracil, Levofolinate
mFOLFIRINOX
Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin
Gem/nab-PTX
Gemcitabine, nab-Paclitaxel
Locations (7)
Aichi Medical University Hospital
Nagakute-shi, Aichi, Japan
Tohoku University Hospital
Sendai-shi, Miyagi, Japan
Tokyo Medical University Hospita
Shinjuku-ku, Tokyo, Japan
Toyama University Hospital
Toyama-shi, Toyama, Japan
Wakayama Medical University Hospital
Wakayama-shi, Wakayama, Japan
Yokohama City University Medical Center
Yokohama-shi, Kanagawa, Japan
Kanagawa Cancer Center
Yokohama-shi, Kanagawa, Japan